The DOI matches its Crossref record; 35 of the 36 references it cites were found in a registry or an index.
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
Open accessAbstract
Background Patients with squamous non-small-cell lung cancer that is refractory to multiple treatments have poor outcomes. We assessed the activity of nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, for patients with advanced, refractory, squamous non-small-cell lung cancer.Methods We did this phase 2, single-arm trial at 27 sites (academic, hospital, and private cancer centres) in France, Germany, Italy, and USA. Patients who had received two or more previous treatments received intravenous nivolumab (3 mg/kg) every 2 weeks until progression or unacceptable toxic effects. The primary endpoint was the proportion of patients with a confirmed objective response as assessed by an independent radiology review committee. We included all treated patients in the analyses. This study is registered with ClinicalTrials.gov, number NCT01721759.Findings Between Nov 16, 2012, and July 22, 2013, we enrolled and treated 117 patients. 17 (14·5%, 95% CI 8·7-22·2) of 117 patients had an objective response as assessed by an independent radiology review committee. Median time to response was 3·3 months (IQR 2·2-4·8), and median duration of response was not reached (95% CI 8·31-not applicable); 13 (77%) of 17 of responses were ongoing at the time of analysis. 30 (26%) of 117 patients had stable disease (median duration 6·0 months, 95% CI 4·7-10·9). 20 (17%) of 117 patients reported grade 3-4 treatment-related adverse events, including: fatigue (five [4%] of 117 patients), pneumonitis (four [3%]), and diarrhoea (three [3%]). There were two treatment-associated deaths caused by pneumonia and ischaemic stroke that occurred in patients with multiple comorbidities in the setting of progressive disease.Interpretation Nivolumab has clinically meaningful activity and a manageable safety profile in previously treated patients with advanced, refractory, squamous non-small cell lung cancer. These data support the assessment of nivolumab in randomised, controlled, phase 3 studies of first-line and second-line treatment.Funding Bristol-Myers Squibb.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The expression of PD-L1 was neither prognostic nor predictive of clinical benefit in a retrospective analysis using various cut points in this study.”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [97]
Experimental — accuracy not yet measuredIn the citing paper
“Nivolumab (BMS-936558, ONO-4538, or MDX1106, trade name Opdivo; Bristol-Myers Squibb, Princeton, NJ, USA) is a first-in-class fully human immunoglobulin G4 (IgG4) monoclonal antibody (mAb) inhibitor that suppresses PD-1 activity through selectively targeting and blocking the interaction between ligands (PD-L1 and PD-L2) and PD-1 receptor [35].”
From Immune Checkpoint Inhibitors in Cancer Therapy (2022) · cites this paper as [35]
In the citing paper
“A phase III trial (CheckMate 017) in patients previously treated for SCC compared 3 mg/kg of nivolumab given every 2 weeks with docetaxel, showing an improvement of 3.2 months [97,98]”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [97]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C. D., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,468
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
Clopper, C. J., & Pearson, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,327
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Self-citation
Cited by
Sorted by citations
Items 301–400 of 1,000
PD‐1 Pathway Inhibitors: Immuno‐Oncology Agents for Restoring Antitumor Immune Responses
Medina, P. J., & Adams, V. R. (2016) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1714 · Cited by 90
Expression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients
Arrieta, O. G., Montes-Servín, E., Hernandez‐Martinez, J., Cardona, A. F., Casas-Ruiz, E., Crispín, J. C., Motola, D., Flores‐Estrada, D., & Barrera, L. (2017) · Oncotarget · doi:10.18632/oncotarget.22025 · Cited by 88
Immunotherapy in non-small cell lung cancer: Past, present, and future directions
Punekar, S. R., Shum, E., Grello, C., Lau, S. C. M., & Velcheti, V. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.877594 · Cited by 89
Treatment of advanced squamous cell carcinoma of the lung: a review.
Derman, B. A., Mileham, K. F., Bonomi, P., Batus, M., & Fidler, M. J. (2015) · PubMed · doi:10.3978/j.issn.2218-6751.2015.06.07 · Cited by 90
Tone, M., Izumo, T., Awano, N., Kuse, N., Inomata, M., Jo, T., Yoshimura, H., Minami, J., Takada, K., Miyamoto, S., et al. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13187 · Cited by 88
Fang, W., Hong, S., Chen, N., He, X., Zhan, J., Qin, T., Zhou, T., Hu, Z., Ma, Y., Zhao, Y., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5028 · Cited by 86
Takeuchi, Y., Tanemura, A., Tada, Y., Katayama, I., Kumanogoh, A., & Nishikawa, H. (2017) · International Immunology · doi:10.1093/intimm/dxx073 · Cited by 88
Bukhari, S., Henick, B. S., WINCHESTER, R. J., Lerrer, S., Adam, K. R., Gartshteyn, Y., Maniar, R., Lin, Z., Khodadadi‐Jamayran, A., Tsirigos, A., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100868 · Cited by 93
Self-citationMyeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade
Peranzoni, E., Ingangi, V., Masetto, E., Pinton, L., & Marigo, I. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01590 · Cited by 85
Immune Checkpoint Inhibitors Side Effects and Management
Kourié, H. R., & Klastersky, J. A. (2016) · Immunotherapy · doi:10.2217/imt-2016-0029 · Cited by 83
Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy
Loo, K. L., Tsai, K. K., Mahuron, K. M., Liu, J., Pauli, M. L., Sandoval, P. M., Nosrati, A., Lee, J., Chen, L., Hwang, J. J., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.93433 · Cited by 84
Li, A., Barsoumian, H. B., Schoenhals, J. E., Cushman, T. R., Caetano, M. S., Wang, X., Valdecanas, D. R., Niknam, S., Younes, A. I. A., Li, G., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.05.005 · Cited by 83
Lin, G., Fan, X., Zhu, W., Huang, C., Zhuang, W., Xu, H., Lin, X., Hu, D., Huang, Y., Jiang, K., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20233 · Cited by 83
Inflammatory and Infectious Syndromes Associated With Cancer Immunotherapies
Fishman, J. A., Hogan, J. I., & Maus, M. V. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy1025 · Cited by 83
Patel, J. J., Levy, D. A., Nguyen, S. A., Knochelmann, H. M., & Day, T. A. (2019) · Head & Neck · doi:10.1002/hed.26036 · Cited by 83
Recent Advances and Challenges in the Treatment of Rhabdomyosarcoma
Miwa, S., Yamamoto, N., Hayashi, K., Takeuchi, A., Igarashi, K., & Tsuchiya, H. (2020) · Cancers · doi:10.3390/cancers12071758 · Cited by 82
Song, P., Zhang, D., Cui, X., & Zhang, L. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13541 · Cited by 84
Zhang, M., Fan, Y., Nie, L., Wang, G., Sun, K., & Cheng, Y. (2022) · CHEST Journal · doi:10.1016/j.chest.2021.12.656 · Cited by 82
Beyond Melanoma: Inhibiting The PD-1/PD-L1 Pathway in Solid Tumors
Gentzler, R. D., Hall, R. D., Kunk, P. R., Gaughan, E. M., Dillon, P. M., Slingluff, C. L., & Rahma, O. E. (2016) · Immunotherapy · doi:10.2217/imt-2015-0029 · Cited by 81
Immune-based Therapies for Non-small Cell Lung Cancer
Rafei, H., El-Bahesh, E., Finianos, A. N., Nassereddine, S., & Tabbara, I. A. (2017) · Anticancer Research · doi:10.21873/anticanres.11330 · Cited by 81
Pitfalls in the radiological response assessment of immunotherapy
Beer, L., Hochmair, M. J., & Prosch, H. (2018) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-018-0389-x · Cited by 81
Current Insights into Combination Therapies with MAPK Inhibitors and Immune Checkpoint Blockade
Shin, M. H., Kim, J., Lim, S. A., Kim, J., & Lee, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072531 · Cited by 82
Shao, J., Ma, J., Zhang, Q., Li, W., & Wang, C. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.02.006 · Cited by 85
Cancer Immunology and Immunotherapy
Sukari, A. W., Nagasaka, M., Al‐Hadidi, A., & Lum, L. G. (2016) · Anticancer Research · doi:10.21873/anticanres.11144 · Cited by 81
Melosky, B. L., Chu, Q. S.-C., Juergens, R. A., Leighl, N. B., McLeod, D., & Hirsh, V. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.8049 · Cited by 81
Li, H., Yang, Z., & Guo, Q. (2021) · Cell Communication and Signaling · doi:10.1186/s12964-021-00789-w · Cited by 86
Pinato, D. J., Shiner, R. J., White, S. D. T., Black, J. R., Trivedi, P. S., Stebbing, J., Sharma, R., & Mauri, F. A. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1213934 · Cited by 80
Trends and advances in tumor immunology and lung cancer immunotherapy
Aldarouish, M., & Wang, C. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0439-3 · Cited by 81
Rivero, J. D., Cordes, L. M., Kłubo-Gwieździńska, J., Madan, R. A., Nieman, L. K., & Gulley, J. L. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0470 · Cited by 79
Rice, A. E., Latchman, Y. E., Balint, J. P., Lee, J. H., Gabitzsch, E. S., & Jones, F. R. (2015) · Cancer Gene Therapy · doi:10.1038/cgt.2015.40 · Cited by 81
Goeree, R. A., Villeneuve, J., Goeree, J., Penrod, J. R., Orsini, L. S., & Monfared, A. A. T. (2016) · Journal of Medical Economics · doi:10.3111/13696998.2016.1151432 · Cited by 79
Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy
Li, X., Song, W., Shao, C., Shi, Y., & Han, W. (2018) · Cellular and Molecular Immunology · doi:10.1038/s41423-018-0086-z · Cited by 79
Huang, J., Fan, Q., Lu, P., Ying, J., Ma, C., Liu, W., Liu, Y., Tan, F., & Sun, Y. P. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.02.020 · Cited by 78
Immune checkpoint inhibitor-related pneumonitis: research advances in prediction and management
Lin, M., Zang, D., Liu, C., Han, X., & Chen, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1266850 · Cited by 79
Li, X., Li, M., Lian, Z., Zhu, H., Kong, L., Wang, P., & Yu, J. (2016) · Targeted Oncology · doi:10.1007/s11523-016-0451-8 · Cited by 77
Leveraging the immune system to treat advanced thyroid cancers
French, J. D., Bible, K. C., Spitzweg, C., Haugen, B. R., & Ryder, M. M. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30277-7 · Cited by 77
O’Malley, D. P., Yang, Y., Boisot, S., Sudarsanam, S., Wang, J., Chizhevsky, V., Zhao, G., Arain, S., & Weiss, L. M. (2019) · Modern Pathology · doi:10.1038/s41379-019-0210-3 · Cited by 76
Jagieła, J., Bartnicki, P., & Rysz, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094618 · Cited by 76
Agrawal, S., Statkevich, P., Bajaj, G., Feng, Y., Saeger, S., Desai, D. D., Park, J., Waxman, I. M., Roy, A., & Gupta, M. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.818 · Cited by 76
Immune Checkpoint Inhibitor-Induced Colitis: Diagnosis and Management
Prieux‐Klotz, C., Dior, M., Damotte, D., Dréanic, J., Brieau, B., Brézault, C., Abitbol, V., Chaussade, S., & Coriat, R. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0495-4 · Cited by 76
Lan, B., Ma, C., Zhang, C., Chai, S., Wang, P., Ding, L., & Wang, K. (2018) · Oncotarget · doi:10.18632/oncotarget.23969 · Cited by 76
Kazandjian, D. G., Blumenthal, G. M., Luo, L., He, K., Fran, I., Lemery, S. J., & Pazdur, R. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0101 · Cited by 75
PD-1/PD-L1 Axis in Lung Cancer
Santini, F. C., & Hellmann, M. D. (2018) · The Cancer Journal · doi:10.1097/ppo.0000000000000300 · Cited by 77
Watanabe, E., Nishida, O., Kakihana, Y., Odani, M., Okamura, T., Harada, T., & Oda, S. (2019) · Shock · doi:10.1097/shk.0000000000001443 · Cited by 75
Shukuya, T., Mori, K. P., Amann, J. M., Bertino, E. M., Otterson, G. A., Shields, P. G., Morita, S., & Carbone, D. P. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.07.017 · Cited by 74
Self-citationTrial watch: immune checkpoint blockers for cancer therapy
Vanpouille-Box, C., Lhuillier, C., Bezu, L., Aranda, F., Yamazaki, T., Kepp, O., Fucikova, J., Spisek, R., Demaria, S., Formenti, S. C., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1373237 · Cited by 73
Sui, X., Ma, J., Han, W., Wang, X., Fang, Y., Li, D., Pan, H., & Zhang, L. (2015) · Oncotarget · doi:10.18632/oncotarget.5107 · Cited by 74
Targeting the PD-1/PD-L1 Axis for the Treatment of Non-Small-Cell Lung Cancer
Meyers, D. E., Bryan, P., Banerji, S. O., & Morris, D. G. (2018) · Current Oncology · doi:10.3747/co.25.3976 · Cited by 74
Mizuno, K., Ito, T., Ishigami, M., Ishizu, Y., Kuzuya, T., Honda, T., Kawashima, H., Inukai, Y., Toyoda, H., Yokota, K., et al. (2020) · Journal of Gastroenterology · doi:10.1007/s00535-020-01677-9 · Cited by 73
Kreatsoulas, D. C., Bolyard, C. M., Wu, B. X., Çam, H., Giglio, P., & Li, Z. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01298-0 · Cited by 75
Tumor immune microenvironment characterization and response to anti-PD-1 therapy.
Santarpía, M., & Karachaliou, N. (2015) · Europe PMC (PubMed Central) · doi:10.7497/j.issn.2095-3941.2015.0022 · Cited by 73
Brown, Z. J., Heinrich, B., Steinberg, S. M., Yu, S. J., & Greten, T. F. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0298-2 · Cited by 73
Honda, Y., Otsuka, A., Ono, S., Yamamoto, Y., Seidel, J. A., Morita, S., Hirata, M., Kataoka, T. R., Takenouchi, T., Fujii, K., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1253657 · Cited by 72
Edlund, K., Madjar, K., Mattsson, J. S. M., Djureinovic, D., Lindskog, C., Brunnström, H., Koyi, H., Brandén, E., Jirström, K., Pontén, F., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.12.022 · Cited by 72
Hiltbrunner, S., Cords, L., Kasser, S., Freiberger, S. N., Kreutzer, S., Toussaint, N. C., Grob, L., Opitz, I., Messerli, M., Zoche, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40745-5 · Cited by 78
Qin, A., Coffey, D. G., Warren, E. H., & Ramnath, N. (2016) · Cancer Medicine · doi:10.1002/cam4.819 · Cited by 72
O'Kane, G. M., Labbé, C., Doherty, M. K., Young, K., Albaba, H., & Leighl, N. B. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0164 · Cited by 72
The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer
Horn, L., Reck, M., & Spigel, D. R. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0523 · Cited by 73
Self-citationImmune checkpoint inhibitors: new strategies to checkmate cancer
Wilson, R., Evans, T. R. J., Fraser, A. R., & Nibbs, R. J. B. (2017) · Clinical & Experimental Immunology · doi:10.1111/cei.13081 · Cited by 72
Ninatti, G., Kirienko, M., Neri, E., Sollini, M., & Chiti, A. (2020) · Diagnostics · doi:10.3390/diagnostics10060359 · Cited by 72
Pathogenesis, Clinical Manifestations and Management of Immune Checkpoint Inhibitors Toxicity
Inno, A., Metro, G., Bironzo, P., Grimaldi, A. M., Grego, E., Nunno, V. D., Picasso, V., Massari, F., & Gori, S. (2017) · Tumori Journal · doi:10.5301/tj.5000625 · Cited by 70
Do immune checkpoint inhibitors need new studies methodology?
Ferrara, R., Pilotto, S., Caccese, M., Grizzi, G., Sperduti, I., Giannarelli, D., Milella, M., Besse, B., Tortora, G., & Bria, E. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.01.131 · Cited by 69
Okada, N., Matsuoka, R., Sakurada, T., Goda, M., Chuma, M., Yagi, K., Zamami, Y., Nishioka, Y., & Ishizawa, K. (2020) · Scientific Reports · doi:10.1038/s41598-020-70743-2 · Cited by 69
Nishio, M., Hida, T., Atagi, S., Sakai, H., Nakagawa, K., Takahashi, T., Nogami, N., Saka, H., Takenoyama, M., Maemondo, M., et al. (2017) · ESMO Open · doi:10.1136/esmoopen-2016-000108 · Cited by 69
Neuromuscular complications of immune checkpoint inhibitor therapy
Kolb, N., Trevino, C., Waheed, W., Sobhani, F., Landry, K. K., Thomas, A. A., & Hehir, M. (2018) · Muscle & Nerve · doi:10.1002/mus.26070 · Cited by 68
Antimicrobial peptides as novel therapeutics for non-small cell lung cancer
Kunda, N. K. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.11.012 · Cited by 68
Yang, F., Wang, J., Wang, Y., Liu, B., & Molina, J. R. (2021) · Cancers · doi:10.3390/cancers14010109 · Cited by 73
Shin, J. M., Lee, C., Son, S., Kim, C. H., Lee, J. A., Ko, H., Shin, S., Song, S. H., Park, S., Bae, J., et al. (2021) · Advanced Science · doi:10.1002/advs.202103245 · Cited by 68
Drug-Related Pneumonitis in the Era of Precision Cancer Therapy
Nishino, M., Hatabu, H., Hodi, F. S., & Ramaiya, N. H. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00026 · Cited by 68
Leem, G., Park, J., Jeon, M., Kim, E.-S., Kim, S. W., Lee, Y. J., Choi, S. J., Choi, B., Park, S., Jung, I., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001650 · Cited by 68
Bevacizumab in the treatment of NSCLC: patient selection and perspectives
RUSSO, A. E., Priolo, D., Antonelli, G., Libra, M., McCubrey, J. A., & Ferraù, F. (2017) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s110306 · Cited by 67
Shevtsov, M. A., Pitkin, E., Ischenko, A. M., Stangl, S., Khachatryan, W. А., Galibin, O. V., Edmond, S., Lobinger, D., & Multhoff, G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00454 · Cited by 69
Yang, L., Xue, R., & Pan, C. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s190168 · Cited by 69
Advances in immunotherapy for treatment of lung cancer.
Alvarez, J. G. B., González‐Cao, M., Karachaliou, N., Santarpía, M., Viteri, S., Teixidó, C., & Rosell, R. (2015) · Europe PMC (PubMed Central) · doi:10.7497/j.issn.2095-3941.2015.0032 · Cited by 67
Deng, S., Sun, Z., Qiao, J., Liang, Y., Liu, L., Dong, C., Shen, A., Wang, Y., Tang, H., Fu, Y., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.132000 · Cited by 67
Multhoff, G., Seier, S., Stangl, S., Sievert, W., Shevtsov, M. A., Werner, C., Pockley, A. G., Blankenstein, C., Hildebrandt, M., Offner, R., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1141 · Cited by 66
Self-citationAn unexpected role for p53 in regulating cancer cell–intrinsic PD-1 by acetylation
Cao, Z., Kon, N., Liu, Y., Xu, W., Wen, J., Yao, H., Zhang, M., Wu, Z., Yan, X., Zhu, W., et al. (2021) · Science Advances · doi:10.1126/sciadv.abf4148 · Cited by 67
Cyclosporine for Dry Eye Associated With Nivolumab
Nguyen, A. T., Elia, M., Materin, M. A., Sznol, M., & Chow, J. (2016) · Cornea · doi:10.1097/ico.0000000000000724 · Cited by 66
Park, J., Kwon, M., Kim, K. H., Kim, T.-S., Hong, S.-H., Kim, C. G., Kang, S., Moon, J. H., Kim, E. H., Park, S., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2564 · Cited by 68
PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC)
Jiang, L., Su, X., Zhang, T., Yin, X., Zhang, M., Fu, H., Han, H., Sun, Y., Dong, L., Qian, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15839 · Cited by 69
Li, C., Huang, C., Mok, T. S. K., Zhuang, W., Xu, H., Miao, Q., Fan, X., Zhu, W., Huang, Y., Lin, X., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.07.015 · Cited by 65
Therapeutic Targets for Bone and Soft-Tissue Sarcomas
Miwa, S., Yamamoto, N., Hayashi, K., Takeuchi, A., Igarashi, K., & Tsuchiya, H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20010170 · Cited by 66
Carbognin, L., Pilotto, S., Nortilli, R., Brunelli, M., Nottegar, A., Sperduti, I., Giannarelli, D., Bria, E., & Tortora, G. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0307 · Cited by 65
Bae, E., Seo, H., Kim, B. S., Choi, J.-W., Jeon, I., Shin, K.-S., Koh, C., Song, B., Kim, I., Min, B. S., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0734 · Cited by 65
The evolving toxicity profile of SBRT for lung cancer
Thompson, M., & Rosenzweig, K. E. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.10.06 · Cited by 65
Zou, M., Peng, A.-B., Lv, G., Wang, X., Li, J., She, X., & Jiang, Y. (2016) · Europe PMC (PubMed Central) · doi:10.13140/rg.2.1.1007.0649 · Cited by 65
Hepatitis B reactivation in a long-term nonprogressor due to nivolumab therapy
Lake, A. C. (2017) · AIDS · doi:10.1097/qad.0000000000001599 · Cited by 64
Personalized medicine in non-small cell lung cancer: a review from a pharmacogenomics perspective
Jiang, W., Cai, G., Hu, P. C., & Wang, Y. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.04.005 · Cited by 67
Beer, L., Hochmair, M. J., Haug, A. R., Schwabel, B., Kifjak, D., Wadsak, W., Fuereder, T., Fabikan, H., Fazekas, A. S., Schwab, S., et al. (2019) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000002603 · Cited by 64
Immune checkpoint inhibitors in non-small cell lung cancer: A bird's eye view
Memon, H., & Patel, B. M. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116713 · Cited by 66
IgA Nephropathy after Nivolumab Therapy for Postoperative Recurrence of Lung Squamous Cell Carcinoma
Kishi, S., Minato, M., Saijo, A., Murakami, N., Tamaki, M., Matsuura, M., Murakami, T., Nagai, K., Abe, H., Nishioka, Y., et al. (2017) · Internal Medicine · doi:10.2169/internalmedicine.9814-17 · Cited by 63
Toxicity profiles of immunotherapy
Cousin, S., Sénéschal, J., & Italiano, A. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.07.005 · Cited by 63
Rossi, S., Toschi, L., Castello, A., Grizzi, F., Mansi, L., & Lopci, E. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3802-5 · Cited by 64
Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer
Su, C., Wang, H., Liu, Y., Guo, Q., Zhang, L., Li, J., Zhou, W., Yan, Y., Zhou, X., & Zhang, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.554313 · Cited by 63
Hida, T., Nishio, M., Nogami, N., Ohe, Y., Nokihara, H., Sakai, H., Satouchi, M., Nakagawa, K., Takenoyama, M., Isobe, H., et al. (2017) · Cancer Science · doi:10.1111/cas.13225 · Cited by 62
Almawash, S. (2025) · Cancers · doi:10.3390/cancers17050880 · Cited by 69
Immune checkpoint blockade for hematologic malignancies: a review
Pianko, M. J., Liu, Y., Bagchi, S., & Lesokhin, A. M. (2017) · Stem Cell Investigation · doi:10.21037/sci.2017.03.04 · Cited by 65
Neopterin as a biomarker of immune response in cancer patients
Melichar, B., Spisarová, M., Bartoušková, M., Krčmová, L. K., Javorská, L., & Študentová, H. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.06.29 · Cited by 62
Lü, J., Li, L., Lan, Y., Liang, Y., & Meng, H. (2019) · Cancer Medicine · doi:10.1002/cam4.2661 · Cited by 63
Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy
Goleva, E., Lyubchenko, T. A., Kraehenbuehl, L., Lacouture, M. E., Leung, D. Y. M., & Kern, J. A. (2021) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2021.03.003 · Cited by 62
Metadata
- Authors
- Rizvi, N. A., Mazières, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., Horn, L., Lena, H., Minenza, E., Mennecier, B., Otterson, G. A., Campos, L. T., Gandara, D. R., Levy, B. P., Nair, S. G., Zalcman, G., Wolf, J., Souquet, P.-J., Baldini, E., Cappuzzo, F., Chouaid, C., Dowlati, A., Sanborn, R., Lopez-Chavez, A., Grohe, C., Huber, R. M., Harbison, C. T., Baudelet, C., Lestini, B. J., & Ramalingam, S. S.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Centre Hospitalier Universitaire de Toulouse (FR)
- Institut Gustave Roussy (FR)
- University of North Carolina at Chapel Hill (US)
- Roswell Park Comprehensive Cancer Center (US)
- Moffitt Cancer Center (US)
- Vanderbilt University (US)
- Azienda Ospedaliera S.Maria (IT)
- Hôpital Civil, Strasbourg (FR)
- The Ohio State University Wexner Medical Center (US)
- UC Davis Comprehensive Cancer Center (US)
- Mount Sinai Beth Israel (US)
- Lehigh Valley Hospital (US)
- Centre Hospitalier Universitaire de Caen Normandie (FR)
- University Hospital Cologne (DE)
- Hospices Civils de Lyon (FR)
- Ospedale di Livorno (IT)
- University Hospitals of Cleveland (US)
- Providence Portland Medical Center (US)
- German Center for Lung Research (DE)
- Princeton University (US)
- Emory University (US)
- Corresponding author
- Rizvi, Naiyer A
- ORCID
- Rizvi, Naiyer A
- Mazières, Julien
- Planchard, David
- Stinchcombe, Thomas E
- Dy, Grace K
- Antonia, Scott J
- Horn, Leora
- Mennecier, Bertrand
- Otterson, Gregory A
- Campos, Luis T
- Gandara, David R
- Levy, Benjamin P
- Nair, Suresh G
- Zalcman, Gérard
- Wolf, Jürgen
- Cappuzzo, Federico
- Chouaid, Christos
- Dowlati, Afshin
- Sanborn, Rachel
- Huber, Rudolf M
- Ramalingam, Suresh S
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2015-03
- Volume
- 16
- Issue
- 3
- Pages
- 257-265
- ISSN
- 1470-2045 (ISSN-L)
- PMC
- PMC5726228
- OpenAlex
- W2106511606
- Cited by
- 1,415
- References
- 36
- Citations by year
- 2026: 23 · 2025: 35 · 2024: 62 · 2023: 84 · 2022: 81 · 2021: 114 · 2020: 128 · 2019: 135 · 2018: 179 · 2017: 228 · 2016: 229 · 2015: 111
- FWCI
- 108.74
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P30CA076292)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- PD-1 inhibitors, lung squamous cell carcinoma, refractory lung cancer, objective response rate, treatment safety, pneumonitis, immune-related adverse events, immune checkpoint blockade, non-relapse mortality, ischemic stroke, pneumonia, fatigue, diarrhea, previously treated patients, duration of response, stable disease, time to response
- MeSH terms
- Nivolumab, Aged, Antibodies, Monoclonal, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Drug Administration Schedule, Europe, Female, Humans, Infusions, Intravenous, Lung Neoplasms, Male, Middle Aged, Risk Factors, Time Factors, United States, Signal Transduction, Comorbidity, Treatment Outcome, Disease Progression, Disease-Free Survival, Kaplan-Meier Estimate, Molecular Targeted Therapy, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
